Literature DB >> 426027

Organophosphorous neuropathy. I. A teased-fiber study of the spatio-temporal spread of axonal degeneraion.

T W Bouldin, J B Cavanagh.   

Abstract

The spatio-temporal spread of axonal degeneration in organophosphorous neuropathy has been studied by means of the teased-fiber technique. Young adult cats were given a single intraperitoneal injection of di-isopropylfluorophosphate (DFP) and were killed 14, 18, 20, 21, and 28 days later by intracardiac perfusion with aldehydes. The cats developed clinical signs of delayed neurotoxicity 16 to 18 days after DFP injection. A histologic survey of the central and peripheral nervous systems revealed that the topographic distribution of axonal degeneration was characteristic of a dying-back neuropathy. In teased-fiber preparations from the left recurrent laryngeal nerve, we found that the axonal degeneration was initially focal and nonterminal but that the axonal degeneration subsequently spread in a somatofugal direction to involve the entire distal axon. Nerve fibre varicosities and paranodal demyelination preceded the axonal degeneration. It is concluded that neurotoxic organophosphates induce a focal, distal but not terminal axonal degeneration. This "chemical transection" of the axon then precipitates wallerian degeneration of the more distal axon. Thus, the traditional hypothesis that dying-back neuropathies evolve from a retrograde axonal degeneration is not valid for organophosphorous neuropathy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 426027      PMCID: PMC2042239     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  11 in total

1.  PERIPHERAL NERVE CHANGES IN ORTHO-CRESYL PHOSPHATE POISONING IN THE CAT.

Authors:  J B CAVANAGH
Journal:  J Pathol Bacteriol       Date:  1964-04

2.  CHANGES IN THE CENTRAL NERVOUS SYSTEM IN THE CAT AS THE RESULT OF TRI-O-CRESYL PHOSPHATE POISONING.

Authors:  J B CAVANAGH; G N PATANGIA
Journal:  Brain       Date:  1965-03       Impact factor: 13.501

3.  Early course of Wallerian degeneration in myelinated fibres of the rat phrenic nerve.

Authors:  L Lubińska
Journal:  Brain Res       Date:  1977-07-08       Impact factor: 3.252

4.  Segmental demyelination secondary to axonal degeneration in uremic neuropathy.

Authors:  P J Dyck; W J Johnson; E H Lambert; P C O'Brien
Journal:  Mayo Clin Proc       Date:  1971-06       Impact factor: 7.616

5.  The spatio-temporal pattern of Wallerian degeneration in mammalian peripheral nerves.

Authors:  J R Donat; H M Wiśniewski
Journal:  Brain Res       Date:  1973-04-13       Impact factor: 3.252

6.  The pathogenesis of dying-back polyneuropathies. I. An ultrastructural study of experimental tri-ortho-cresyl phosphate intoxication in the cat.

Authors:  J Prineas
Journal:  J Neuropathol Exp Neurol       Date:  1969-10       Impact factor: 3.685

Review 7.  The significance of the "dying back" process in experimental and human neurological disease.

Authors:  J B Cavanagh
Journal:  Int Rev Exp Pathol       Date:  1964

8.  Ultrastructural studies of the dying-back process. III. The evolution of experimental peripheral giant axonal degeneration.

Authors:  P S Spencer; H H Schaumburg
Journal:  J Neuropathol Exp Neurol       Date:  1977 Mar-Apr       Impact factor: 3.685

9.  Organophosphorous neuropathy. II. A fine-structural study of the early stages of axonal degeneration.

Authors:  T W Bouldin; J B Cavanagh
Journal:  Am J Pathol       Date:  1979-02       Impact factor: 4.307

10.  The delayed neurotoxic effect of some organophosphorus compounds. Identification of the phosphorylation site as an esterase.

Authors:  M K Johnson
Journal:  Biochem J       Date:  1969-10       Impact factor: 3.857

View more
  20 in total

1.  Consequences of neurite transection in vitro.

Authors:  Nurettin Cengiz; Gürkan Oztürk; Ender Erdoğan; Aydın Him; Elif Kaval Oğuz
Journal:  J Neurotrauma       Date:  2012-09-27       Impact factor: 5.269

2.  Constructs of human neuropathy target esterase catalytic domain containing mutations related to motor neuron disease have altered enzymatic properties.

Authors:  Nichole D Hein; Jeanne A Stuckey; Shirley R Rainier; John K Fink; Rudy J Richardson
Journal:  Toxicol Lett       Date:  2010-04-09       Impact factor: 4.372

3.  Late onset isofenphos neurotoxicity.

Authors:  A Catz; B Chen; I Jutrin; L Mendelson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-10       Impact factor: 10.154

4.  Morphometric evaluation of primary sensory neurons in experimental p-bromophenylacetylurea intoxication.

Authors:  A Ohnishi; M Ikeda
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

5.  Organophosphate risk assessment: field testing of DEE with the scaleless chicken.

Authors:  B W Wilson; C M Cisson; W R Randall; J E Woodrow; J N Seiber; J B Knaak
Journal:  Bull Environ Contam Toxicol       Date:  1980-06       Impact factor: 2.151

6.  Ethylene oxide induces central-peripheral distal axonal degeneration of the lumbar primary neurones in rats.

Authors:  A Ohnishi; N Inoue; T Yamamoto; Y Murai; H Hori; M Koga; I Tanaka; T Akiyama
Journal:  Br J Ind Med       Date:  1985-06

Review 7.  Prophylaxis and the mechanism for the initiation of organophosphorous compound-induced delayed neurotoxicity.

Authors:  C D Carrington
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

8.  Neuropathology of organophosphate-induced delayed neuropathy (OPIDN) in young chicks.

Authors:  K A Funk; J D Henderson; C H Liu; R J Higgins; B W Wilson
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

9.  Organophosphorous neuropathy. II. A fine-structural study of the early stages of axonal degeneration.

Authors:  T W Bouldin; J B Cavanagh
Journal:  Am J Pathol       Date:  1979-02       Impact factor: 4.307

10.  The effects of phenylmethanesulfonyl fluoride on delayed organophosphorus neuropathy.

Authors:  T Baker; H E Lowndes; M K Johnson; I C Sandborg
Journal:  Arch Toxicol       Date:  1980-12       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.